Evidence map›Paper›PMID 34079900›Full record

ArticleACS central science2021

Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization.

Hanan Alwaseem, Simone Giovani, Michele Crotti, Kevin Welle, Craig T Jordan, Sina Ghaemmaghami, Rudi Fasan

Abstract read
In one paragraph

Article in ACS central science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Biomedicines · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanan AlwaseemDepartment of Chemistry, University of Rochester, Rochester, New York 14627, United States.
Simone GiovaniDepartment of Chemistry, University of Rochester, Rochester, New York 14627, United States.ORCID 0000-0003-0229-7816
Michele CrottiDepartment of Chemistry, University of Rochester, Rochester, New York 14627, United States.ORCID 0000-0003-3274-9393
Kevin WelleMass Spectrometry Resource Laboratory, University of Rochester Medical School, Rochester, New York 14627, United States.
Craig T JordanDepartment of Hematology, School of Medicine, University of Colorado, Aurora, Colorado 80045, United States.
Sina GhaemmaghamiMass Spectrometry Resource Laboratory, University of Rochester Medical School, Rochester, New York 14627, United States.ORCID 0000-0002-8696-2950
Rudi FasanDepartment of Chemistry, University of Rochester, Rochester, New York 14627, United States.ORCID 0000-0003-4636-9578

Funding

The prevalence and mechanism of selectivity in basal autophagyR35GM119502 · NIGMS · UNIVERSITY OF ROCHESTER · PI SINA GHAEMMAGHAMI · 2016 to 2026
$5.9M
Selective P450 Oxidation Catalysts for Synthesis of Bioactive MoleculesR01GM098628 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI FASAN, RUDI · 2012 to 2024
$4.7M
Orbitrap Fusion Lumos Mass Spectrometer for UR Proteomics ResearchS10OD025242 · OD · UNIVERSITY OF ROCHESTER · PI GHAEMMAGHAMI, SINA · 2018 to 2018
$1.1M
QExactive for UR Proteomics ResearchS10OD021486 · OD · UNIVERSITY OF ROCHESTER · PI GHAEMMAGHAMI, SINA · 2016 to 2016
$309k
NIGMS NIH HHS R01 GM098628NIGMS NIH HHS R35 GM119502NIH HHS S10 OD021486NIH HHS S10 OD025242
6 · The paper itself

Abstract

The plant-derived sesquiterpene lactone micheliolide was recently found to possess promising antileukemic activity, including the ability to target and kill leukemia stem cells. Efforts toward improving the biological activity of micheliolide and investigating its mechanism of action have been hindered by the paucity of preexisting functional groups amenable for late-stage derivatization of this molecule. Here, we report the implementation of a probe-based P450 fingerprinting strategy to rapidly evolve engineered P450 catalysts useful for the regio- and stereoselective hydroxylation of micheliolide at two previously inaccessible aliphatic positions in this complex natural product. Via P450-mediated chemoenzymatic synthesis, a broad panel of novel micheliolide analogs could thus be obtained to gain structure-activity insights into the effect of C2, C4, and C14 substitutions on the antileukemic activity of micheliolide, ultimately leading to the discovery of "micheliologs" with improved potency against acute myelogenic leukemia cells. These late-stage C-H functionalization routes could be further leveraged to generate a panel of affinity probes for conducting a comprehensive analysis of the protein targeting profile of micheliolide in leukemia cells via chemical proteomics analyses. These studies introduce new micheliolide-based antileukemic agents and shed new light onto the biomolecular targets and mechanism of action of micheliolide in leukemia cells. More broadly, this work showcases the value of the present P450-mediated C-H functionalization strategy for streamlining the late-stage diversification and elucidation of the biomolecular targets of a complex bioactive molecule.

Identifiers

PMID34079900
PMCPMC8161485

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.